Table 11.
Variable | Impact coefficient | Hazard ratio | Standard error | p value | 95% CI (RH) |
---|---|---|---|---|---|
Postmenopausal | -3.54 | 0.28 | 6.08 | 0.56 | 1.9e − 07 (4370) |
Luminal B | -0.76 | 0.46 | 3.14 | 0.81 | 9.8e + 04 (222) |
Intermediate risk | -0.59 | 0.55 | 0.89 | 0.88 | 1.6e + 04 (222) |
High risk | -2.15 | 1.97 | 6.52 | 0.74 | 3.2e − 07 (1850) |
Tamoxifen | -2.35 | 0.12 | 3.39 | 0.49 | 1.2e − 04 (4.15e + 04) |
Tamoxifen-IA | -1.73 | 0.18 | 4.01 | 0.66 | 6.8e − 05 (73.3) |
Tumor size (10.20] | -2.09 | 0.12 | 3.81 | 0.58 | 7.05e − 5 (218) |
Tumor size (20,30] | 0.22 | 1.25 | 5.01 | 0.96 | 7.05e − 05 (2.29e + 04) |
Tumor size (30,100] | -2.18 | 0.11 | 4.38 | 0.62 | 6.81e − 05 (602) |
Ki67 borderline | 2.05 | 7.78 | 4.92 | 0.68 | 4.98e − 04 (1.21e + 05) |
Ki67 high | 2.11 | 8.23 | 4.04 | 0.6 | 0.003 2 (27e + 04) |
Hormone receptor EP + RP | 1.48 | 4.39 | 4 | 0.71 | 1730 1.1(1e + 04) |
Age (44.56] | 2.16 | 8.66 | 5.63 | 0.7 | 1.37e − 04 (5.45e + 05) |
Age (56.69] | 3.48 | 32.35 | 6.41 | 0.58 | 1.13e − 04 (9.23e + 06) |
Age (69,100] | 3.76 | 43.11 | 8.4 | 0.65 | 3.03e − 06 (6.13e + 08) |
Nodal status (0.10] | 0.88 | 2.41 | 4.49 | 0.84 | 3.66e − 04 (1.58e + 04) |
Nodal status (10.25] | 1.35 | 3.87 | 6.5 | 0.83 | 1.13e − 05 (1.31e + 06) |
gg extracted (1.11] | 1.05 | 2.84 | 4.42 | 0.81 | 4.86e − 04 (1.66e + 04) |
gg extracted (11.17] | 1.27 | 3.57 | 4.57 | 0.78 | 4.60e − 04 (2.77e + 04) |
gg extracted (17.32] | 8.17 | 1.08 | 5.61 | 0.98 | 1.82e − 05 (6.46e + 04) |